Format

Send to

Choose Destination
PLoS One. 2017 May 4;12(5):e0176834. doi: 10.1371/journal.pone.0176834. eCollection 2017.

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients.

Author information

1
Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea.
2
Graduate School of Medicine, Korea University College of Medicine, Korea University, Seoul, Republic of Korea.
3
Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
4
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
5
Laboratory of Molecular Cell Biology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.

Abstract

BACKGROUND:

Reactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients.

STUDY:

We examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells.

RESULTS:

We observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025).

CONCLUSIONS:

Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.

PMID:
28472059
PMCID:
PMC5417558
DOI:
10.1371/journal.pone.0176834
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center